PureTech Gains FDA Fast Track for LYT-200 in HR-MDS
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
Relapsed/Refractory MDS
Advertisement
Advertisement
Advertisement
LONDON — September 21, 2026 PureTech Health announced the successful completion of an End-of-Phase 1 meeting with the U.S....
Advertisement